Prestige Consumer Healthcare (NYSE:PBH) Downgraded to Hold Rating by StockNews.com

StockNews.com lowered shares of Prestige Consumer Healthcare (NYSE:PBH) from a buy rating to a hold rating in a report released on Tuesday.

A number of other analysts have also recently issued reports on the company. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research report on Monday. DA Davidson reaffirmed a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $85.25.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $83.50 on Tuesday. The company has a market cap of $4.12 billion, a price-to-earnings ratio of 20.32, a PEG ratio of 2.35 and a beta of 0.49. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The company’s fifty day simple moving average is $77.85 and its 200 day simple moving average is $72.35. Prestige Consumer Healthcare has a 1-year low of $57.95 and a 1-year high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same period in the previous year, the business earned $1.07 EPS. Prestige Consumer Healthcare’s revenue for the quarter was down .9% compared to the same quarter last year. On average, research analysts forecast that Prestige Consumer Healthcare will post 4.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares of the company’s stock, valued at $1,505,930. The trade was a 33.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock valued at $3,187,300 in the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors have recently made changes to their positions in the stock. Ariel Investments LLC raised its holdings in Prestige Consumer Healthcare by 10.7% in the 2nd quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock valued at $195,204,000 after acquiring an additional 274,212 shares in the last quarter. Victory Capital Management Inc. raised its stake in Prestige Consumer Healthcare by 9.0% in the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock valued at $142,827,000 after purchasing an additional 171,357 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Prestige Consumer Healthcare by 19.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock worth $113,570,000 after purchasing an additional 255,045 shares during the period. Geode Capital Management LLC grew its stake in Prestige Consumer Healthcare by 4.0% during the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after buying an additional 50,961 shares in the last quarter. Finally, Congress Asset Management Co. increased its stake in Prestige Consumer Healthcare by 7.8% in the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock valued at $62,375,000 after acquiring an additional 62,411 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.